Navigation Links
Genomic Health to Announce Third Quarter 2010 Financial Results and Host Conference Call on Monday, November 8, 2010
Date:10/26/2010

REDWOOD CITY, Calif., Oct. 26 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Monday, November 8 at 4:30 p.m. Eastern Time to discuss its third quarter 2010 financial results. The call and webcast will follow the release of the third quarter financial results after market close.

Conference Call Details

To access the live conference call on November 8 at 4:30 p.m. Eastern Time via phone, please dial (877) 303-7208 from the United States and Canada or +1(224) 357-2389 internationally.  Please dial in approximately ten minutes prior to the start of the call.  A telephone replay will be available beginning approximately two hours after the call through November 15, and may be accessed by dialing (800) 642-1687 from the United States and Canada or +1(706) 645-9291 internationally. The replay passcode is 19819777.

To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the company's Web site at http://investor.genomichealth.com.  Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary.

About Genomic Health, Inc.

Genomic Health, Inc. (NASDAQ: GHDX) is a life science company focused on the global development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched the Oncotype DX® breast cancer test, which has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In addition to the widely adopted Oncotype DX breast cancer test, Genomic Health launched its Oncotype DX colon cancer test in January 2010. As of June 30, 2010, more than 10,000 physicians in over 55 countries had ordered more than 160,000 Oncotype DX tests. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit www.genomichealth.com.

NOTE: The Genomic Health logo, Oncotype and Oncotype DX are trademarks or registered trademarks of Genomic Health, Inc.


'/>"/>
SOURCE Genomic Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dr. Eric Johnson Joins Transgenomic as Medical Director for Laboratory Services
2. WaferGen Names Gary P. Schroth, Ph.D., as New SVP, Genomics Research and Applications
3. Clinical Genomics Pty Ltd and The Garvan Institute of Medical Research Enter into Licensing Agreement
4. Genomas Awarded US Patent for its PhyzioGenomics Platform Technology to Predict Treatment Responses
5. Genomic Health to Present at Two Upcoming Investor Conferences
6. Ingenuity Systems Announces Toxicogenomics Best Practices White Paper
7. J. Craig Venter Institute Hosts Genomics Education Program for DC Metro Area Teachers
8. NeoGenomics Schedules its Q2 2010 Earnings Release for July 29, 2010
9. Sirius Genomics Announces Appointment of Senior Director of Business Development
10. SeqWright Expands Genomics Services Offering Through New Partnership With RainDance Technologies
11. Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... West Point, IA (PRWEB) , ... January 17, ... ... approval from China for Balance™ GT soybeans. The new Balance™ GT Soybean Performance ... tolerance to glyphosate and isoxaflutole, the active ingredient in the new Balance® Bean ...
(Date:1/17/2017)... , Jan. 17, 2017   Pulmatrix, Inc . ... company developing innovative inhaled therapies to address serious pulmonary ... fungal infections in the lungs of CF patients, PUR1900, ... (QIDP) by the U.S. Food & Drug Administration. ... designed to speed the development of novel drugs against ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... the North American Spine Society (NASS)1 demonstrate high fusion rates at 6 ... when PEEK-OPTIMA™ HA Enhanced is used for interbody-fusion devices. The implantable high-performance ...
(Date:1/17/2017)... , Jan. 17, 2017  Protagonist Therapeutics, ... that it has initiated a global Phase 2b ... oral peptide that targets alpha4beta7 integrin. The aim ... is to evaluate the safety/tolerability and efficacy of ... with moderate to severe active disease. ...
Breaking Biology Technology:
(Date:1/11/2017)... 2017 Intoxalock, a leading ignition interlock provider, ... its patent-pending calibration device. With this new technology, Intoxalock ... upload data logs and process repairs at service center ... "Fighting drunk driving through the application of cutting-edge technologies ... but also for the customer who can get back ...
(Date:1/6/2017)... NEWARK, Calif. , Jan. 5, 2017  Delta ... introduced its iris scanning technology for automotive at CES® ... GNTX ) to demonstrate the use of ... to identify and authenticate the driver in a car, ... automobiles during the driving experience. Delta ID ...
(Date:12/22/2016)... , Dec. 20, 2016  As part of its ... the leading personal genetics company, recently released its latest children,s ... . The book focuses on the topics of inheritance and ... Science Standards (NGSS) taught in elementary school classrooms in the ... a series by illustrator Ariana Killoran , whose previous ...
Breaking Biology News(10 mins):